- Home
- AOD vs RIGL Comparison
AOD vs RIGL Comparison
Compare AOD & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AOD | RIGL |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 911.8M |
| IPO Year | 2006 | 2000 |
Fundamental Metrics
Financial Performance| Metric | AOD | RIGL |
|---|---|---|
| Price | $10.10 | $50.65 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $63.00 |
| AVG Volume (30 Days) | ★ 349.2K | 190.3K |
| Earning Date | 01-01-0001 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 1.32 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | N/A | $3.89 |
| Revenue Next Year | N/A | $21.95 |
| P/E Ratio | ★ N/A | $38.19 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $8.76 | $24.84 |
| 52 Week High | $10.85 | $52.24 |
Technical Indicators
Market Signals| Indicator | AOD | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 45.45 | 64.83 |
| Support Level | $9.90 | $44.83 |
| Resistance Level | $10.11 | N/A |
| Average True Range (ATR) | 0.12 | 1.52 |
| MACD | 0.01 | 0.29 |
| Stochastic Oscillator | 53.42 | 99.15 |
Price Performance
Historical ComparisonAbout AOD abrdn Total Dynamic Dividend Fund of Beneficial Interest
Aberdeen Total Dynamic Dividend Fund is a diversified, closed-end management investment company. Its investment objective is to seek high current dividend income. The company also focuses on the long-term growth of capital as a secondary investment objective. The fund invests in foreign securities, including direct investments in securities of foreign issuers and investments in depositary receipts that represent indirect interests in securities of foreign issuers. Its portfolio consists of securities from Information Technology, Financial, Healthcare, and Industrials among other sectors.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.